Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor

Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor

PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract 0- FormulationA 25 - --- FormulationB - --- Formulation C --- Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: CHONG, Ching Wah, KUEHL, Robert, TAN, Heow, ATLURI, Harisha
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator CHONG, Ching Wah
KUEHL, Robert
TAN, Heow
ATLURI, Harisha
description PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract 0- FormulationA 25 - --- FormulationB - --- Formulation C --- Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin 1-yl)piperidin-1-yl)prop-2-en--one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2021240244A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2021240244A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2021240244A13</originalsourceid><addsrcrecordid>eNrjZHAMyEgsyk1MTi0tyUxOzFFIyy_KLc1JLMnMzytWyE9TcCoqLcnPUy9WKKksyi_OzEtVyM7MSyxOVcjMy8hMyizJL-JhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBUCz81JL4h1DjQyMDI1MDIxMTBwNjYlTBQAcaDMR</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor</title><source>esp@cenet</source><creator>CHONG, Ching Wah ; KUEHL, Robert ; TAN, Heow ; ATLURI, Harisha</creator><creatorcontrib>CHONG, Ching Wah ; KUEHL, Robert ; TAN, Heow ; ATLURI, Harisha</creatorcontrib><description>PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract 0- FormulationA 25 - --- FormulationB - --- Formulation C --- Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin 1-yl)piperidin-1-yl)prop-2-en--one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20211028&amp;DB=EPODOC&amp;CC=AU&amp;NR=2021240244A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20211028&amp;DB=EPODOC&amp;CC=AU&amp;NR=2021240244A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CHONG, Ching Wah</creatorcontrib><creatorcontrib>KUEHL, Robert</creatorcontrib><creatorcontrib>TAN, Heow</creatorcontrib><creatorcontrib>ATLURI, Harisha</creatorcontrib><title>Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor</title><description>PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract 0- FormulationA 25 - --- FormulationB - --- Formulation C --- Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin 1-yl)piperidin-1-yl)prop-2-en--one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAMyEgsyk1MTi0tyUxOzFFIyy_KLc1JLMnMzytWyE9TcCoqLcnPUy9WKKksyi_OzEtVyM7MSyxOVcjMy8hMyizJL-JhYE1LzClO5YXS3AzKbq4hzh66qQX58anFBUCz81JL4h1DjQyMDI1MDIxMTBwNjYlTBQAcaDMR</recordid><startdate>20211028</startdate><enddate>20211028</enddate><creator>CHONG, Ching Wah</creator><creator>KUEHL, Robert</creator><creator>TAN, Heow</creator><creator>ATLURI, Harisha</creator><scope>EVB</scope></search><sort><creationdate>20211028</creationdate><title>Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor</title><author>CHONG, Ching Wah ; KUEHL, Robert ; TAN, Heow ; ATLURI, Harisha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2021240244A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>CHONG, Ching Wah</creatorcontrib><creatorcontrib>KUEHL, Robert</creatorcontrib><creatorcontrib>TAN, Heow</creatorcontrib><creatorcontrib>ATLURI, Harisha</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CHONG, Ching Wah</au><au>KUEHL, Robert</au><au>TAN, Heow</au><au>ATLURI, Harisha</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor</title><date>2021-10-28</date><risdate>2021</risdate><abstract>PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract 0- FormulationA 25 - --- FormulationB - --- Formulation C --- Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor -((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo [3,4-d]pyrimidin 1-yl)piperidin-1-yl)prop-2-en--one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_AU2021240244A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A05%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CHONG,%20Ching%20Wah&rft.date=2021-10-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2021240244A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true